In the past week, TERN stock has gone down by -4.84%, with a monthly decline of -7.19% and a quarterly plunge of -33.06%. The volatility ratio for the week is 4.93%, and the volatility levels for the last 30 days are 5.90% for Terns Pharmaceuticals Inc The simple moving average for the past 20 days is -5.91% for TERN’s stock, with a -39.68% simple moving average for the past 200 days.
Is It Worth Investing in Terns Pharmaceuticals Inc (NASDAQ: TERN) Right Now?
The 36-month beta value for TERN is also noteworthy at -0.36. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 2 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”
The public float for TERN is 62.00M, and at present, short sellers hold a 10.41% of that float. The average trading volume of TERN on February 21, 2025 was 1.81M shares.
TERN) stock’s latest price update
Terns Pharmaceuticals Inc (NASDAQ: TERN) has seen a decline in its stock price by -1.43 in relation to its previous close of 4.19. However, the company has experienced a -4.84% decline in its stock price over the last five trading sessions. globenewswire.com reported 2025-02-20 that Seasoned biotechnology CEO brings 25 years of strategic, operational and commercial expertise Seasoned biotechnology CEO brings 25 years of strategic, operational and commercial expertise
Analysts’ Opinion of TERN
Many brokerage firms have already submitted their reports for TERN stocks, with Oppenheimer repeating the rating for TERN by listing it as a “Outperform.” The predicted price for TERN in the upcoming period, according to Oppenheimer is $82 based on the research report published on October 31, 2024 of the previous year 2024.
Mizuho, on the other hand, stated in their research note that they expect to see TERN reach a price target of $16. The rating they have provided for TERN stocks is “Buy” according to the report published on June 22nd, 2023.
Jefferies gave a rating of “Buy” to TERN, setting the target price at $18 in the report published on June 07th of the previous year.
TERN Trading at -20.22% from the 50-Day Moving Average
After a stumble in the market that brought TERN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -63.77% of loss for the given period.
Volatility was left at 5.90%, however, over the last 30 days, the volatility rate increased by 4.93%, as shares sank -11.56% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -35.87% lower at present.
During the last 5 trading sessions, TERN fell by -4.84%, which changed the moving average for the period of 200-days by -21.93% in comparison to the 20-day moving average, which settled at $4.39. In addition, Terns Pharmaceuticals Inc saw -25.45% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TERN starting from Jung Melita Sun, who purchase 2,250 shares at the price of $5.11 back on Nov 30 ’24. After this action, Jung Melita Sun now owns 2,250 shares of Terns Pharmaceuticals Inc, valued at $11,498 using the latest closing price.
Burroughs Amy L., the Chief Executive Officer of Terns Pharmaceuticals Inc, purchase 510 shares at $5.11 during a trade that took place back on Nov 30 ’24, which means that Burroughs Amy L. is holding 19,609 shares at $2,606 based on the most recent closing price.
Stock Fundamentals for TERN
Current profitability levels for the company are sitting at:
- -75.63 for the present operating margin
- 0.47 for the gross margin
The net margin for Terns Pharmaceuticals Inc stands at -66.62. The total capital return value is set at -0.27. Equity return is now at value -28.28, with -27.10 for asset returns.
Based on Terns Pharmaceuticals Inc (TERN), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -57.28. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -38.92.
Currently, EBITDA for the company is -102.27 million with net debt to EBITDA at 2.71. When we switch over and look at the enterprise to sales, we see a ratio of 62.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 32.99.
Conclusion
In summary, Terns Pharmaceuticals Inc (TERN) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
